Appendicitis caused by the metastasis of HER2-positive breast cancer

被引:1
|
作者
Mori, Ryutaro [1 ]
Futamura, Manabu [1 ]
Morimitsu, Kasumi [1 ]
Yoshida, Kazuhiro [1 ]
机构
[1] Gifu Univ, Grad Sch Med, Dept Surg Oncol, 1-1 Yanagido, Gifu 5011194, Japan
来源
SURGICAL CASE REPORTS | 2016年 / 2卷
关键词
Secondary appendiceal neoplasm; Appendicitis; Lobular carcinoma;
D O I
10.1186/s40792-016-0235-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
The appropriate therapy for metastatic breast cancer must be selected based on the immunohistochemical phenotype of the cancer. However, biopsy for metastatic lesions is difficult. We herein report a patient with incidental appendicitis caused by a metastatic breast cancer which was successfully treated with effective therapy chosen based on the pathological diagnosis obtained on resection. The patient was a 56-year-old female with right breast cancer and an immunohistochemical status of estrogen receptor (ER) (+), progesterone receptor (PgR) (+), human epidermal growth factor receptor 2 (HER2) (3+), and Ki67 40 %. She received epirubicin and cyclophosphamide therapy followed by docetaxel and trastuzumab, and total mastectomy with axillary dissection was performed. Thereafter, she received postmastectomy radiation, adjuvant trastuzumab, and adjuvant hormone therapy with letrozole. One year and 8 months after the operation, she developed right hydronephrosis and swollen para-aortic lymph nodes and her hormone therapy was changed to fulvestrant therapy. However, she additionally developed left hydronephrosis and multiple bone metastases, and pertuzumab, trastuzumab, and docetaxel therapy was started. After six cycles, her disease became well-controlled, and maintenance with pertuzumab and trastuzumab was introduced. However, after another 7 months, she developed new vertebral metastasis and acute appendicitis and laparoscopic appendectomy was performed. A pathological investigation of the resected appendix revealed some clusters of atypical cells in the subserosa and muscle layer, which showed an immunohistochemical status of ER (+), PgR (-), HER2 (3+), and E-cadherin (-). These findings led to the diagnosis as appendiceal metastasis of invasive lobular carcinoma (ILC) from the breast. Thereafter, she received trastuzumab-DM1 and her disease was well-controlled again. Appendicitis caused by breast cancer is very rare. However, ILC sometimes develops metastases in the abdominal cavity; an appendiceal tumor should therefore be included in the differential diagnosis. A pathological diagnosis of metastatic tumor could be very useful for selecting the effective therapy.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Appendicitis caused by the metastasis of HER2-positive breast cancer
    Ryutaro Mori
    Manabu Futamura
    Kasumi Morimitsu
    Kazuhiro Yoshida
    Surgical Case Reports, 2 (1)
  • [2] Solitary pituitary metastasis from HER2-positive breast cancer
    Kam, Jeremy
    Kam, Jeffrey
    Mann, G. Bruce
    Phillips, Claire
    Wentworth, John M.
    King, James
    Lindeman, Geoffrey J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E181 - E184
  • [3] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [4] Nanoformulation of lapatinib for HER2-positive breast cancer patients with brain metastasis
    Lee, Joyce S.
    Luo, Juntao
    Desai, Sonal
    Lam, Kit S.
    Li, Tianhong
    CANCER RESEARCH, 2011, 71
  • [5] Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
    Seachrist, Darcie D.
    Sizemore, Steven T.
    Johnson, Emhonta
    Abdul-Karim, Fadi W.
    Bonk, Kristen L. Weber
    Keri, Ruth A.
    BREAST CANCER RESEARCH, 2017, 19
  • [6] Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape
    Soffietti, Riccardo
    Pellerino, Alessia
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 8 - 10
  • [7] Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
    Darcie D. Seachrist
    Steven T. Sizemore
    Emhonta Johnson
    Fadi W. Abdul-Karim
    Kristen L. Weber Bonk
    Ruth A. Keri
    Breast Cancer Research, 19
  • [8] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [9] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
  • [10] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04): : 324 - 326